<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626829</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2022-270</org_study_id>
    <nct_id>NCT05626829</nct_id>
  </id_info>
  <brief_title>Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma</brief_title>
  <official_title>Application of Tranilast as a Radiosensitizer in the Treatment of Radiotherapy Resistant Nasopharyngeal Carcinoma: a Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jian Guan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasopharyngeal carcinoma is one of the high incidence head and neck cancer in Southeast Asia.&#xD;
      Radiotherapy is the main treatment for nasopharyngeal carcinoma, and its response rate can&#xD;
      reach 80~90%. However, for radiotherapy resistant patients with metastasis and recurrence,&#xD;
      the survival prognosis decreased significantly, and the 5-year overall survival rate was only&#xD;
      20% - 40%. Tranilast is an anti-allergic drug, which is clinically used to treat bronchial&#xD;
      asthma and can inhibit fibroblasts α- SMA and type I collagen expression. Through experiments&#xD;
      in vivo and in vitro, the investigators' research group has proved that Tranilast can inhibit&#xD;
      the activity of tumor related fibroblasts, reduce the radiotherapy resistance of&#xD;
      nasopharyngeal carcinoma, and has the radiosensitizing effect of nasopharyngeal carcinoma.&#xD;
      This result has been published in J exp Clin cancer res (if=11.16). The investigators plan to&#xD;
      carry out the clinical transformation of basic research, carry out a prospective intervention&#xD;
      phase II clinical trial, compare the objective remission rate of patients with recurrent&#xD;
      nasopharyngeal carcinoma treated with previous radiotherapy, and explore the safety and&#xD;
      effectiveness of using Tranilast as a radiotherapy sensitizer for radiotherapy to resist the&#xD;
      treatment of nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2022</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Effectiveness of Tranilast in reradiation of recurrent nasopharyngeal carcinoma</measure>
    <time_frame>12 weeks after Tranilast treatment</time_frame>
    <description>we use the objective response rate (ORR), according to the RESIST v1.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Safety of Tranilast in reradiation of recurrent nasopharyngeal</measure>
    <time_frame>12 weeks after Tranilast treatment</time_frame>
    <description>treatment-related adverse events will be assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Recurrent Cancer</condition>
  <arm_group>
    <arm_group_label>Tranilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent Tranilast 100mg 3 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranilast</intervention_name>
    <description>Tranilast capsules 100mg 3 times per day when reradiation</description>
    <arm_group_label>Tranilast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign informed consent&#xD;
&#xD;
          2. At least 18 years old on the date of signing the informed consent&#xD;
&#xD;
          3. Previously received standard radical radiotherapy and chemotherapy&#xD;
&#xD;
          4. Recurrent nasopharyngeal carcinoma in situ or cervical lymph nodes confirmed by&#xD;
             pathological biopsy and imaging examination&#xD;
&#xD;
          5. After multidisciplinary consultation, there was a clear indication for surgery, and&#xD;
             the patient was informed and refused to accept surgical treatment 6）ECOG PS：0/1&#xD;
&#xD;
        7) Laboratory examination confirmed good organ function, which should be carried out within&#xD;
        10 days before the first treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. After evaluation, it does not meet the indications of re-radiotherapy&#xD;
&#xD;
          2. unable to take oral medication&#xD;
&#xD;
          3. Pregnancy or lactation&#xD;
&#xD;
          4. Known allergy to Tranilast&#xD;
&#xD;
          5. Patients who are judged by the researcher as unsuitable to participate in this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guan Jian, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guan Jian, Ph.D.</last_name>
    <phone>+86-1363210224</phone>
    <email>51643930@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern medical university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Guan, M.D.</last_name>
      <phone>86+13632102247</phone>
      <email>guanjian5461@163.com</email>
    </contact>
    <investigator>
      <last_name>Jian Guan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>July 31, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Jian Guan</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranilast</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT05626829/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

